08 11月 2022 by admin in UncategorizedComments Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
07 11月 2022 by admin in UncategorizedComments Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
03 11月 2022 by admin in UncategorizedComments NextCure Provides Update and Reports Third Quarter 2022 Financial Results
03 11月 2022 by admin in UncategorizedComments Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
03 11月 2022 by admin in UncategorizedComments Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
27 10月 2022 by admin in UncategorizedComments NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
17 10月 2022 by admin in UncategorizedComments 科越医药宣布 KP104 用于治疗阵发性睡眠性血红蛋白尿症(PNH)的 II 期 临床试验申请 已获得中国国家药品监督管理局批准
03 10月 2022 by admin in UncategorizedComments 科越医药 KP104 治疗系统性红斑狼疮相关血栓性微血管病(SLE-TMA)的 II 期临床试 验申请获得美国 FDA 批准
